Cardiology – Page 36

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

By MedXY 09/20/2025

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.

Cardiology Clinical Updates news Specialties

Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial

By MedXY 09/20/2025

The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.

Cardiology Clinical Updates news Specialties

HEPA Air Purification Significantly Lowers Systolic Blood Pressure in Adults with Elevated BP Near Highways: Evidence from a Pragmatic Randomized Crossover Trial

By MedXY 09/19/2025

In-home HEPA air purifiers significantly reduce systolic blood pressure by 3.0 mm Hg in adults living near highways with elevated baseline BP, highlighting a practical intervention to mitigate cardiovascular risk from particulate pollution.

Cardiology Clinical Updates

Equally Effective Dual Therapy Combinations for Hypertension in Indian Patients: Insights from a Landmark Randomized Trial

By MedXY 09/19/2025

This multicenter randomized trial in India shows that three dual antihypertensive combinations—amlodipine-perindopril, perindopril-indapamide, and amlodipine-indapamide—are equally effective and well-tolerated for 24-hour blood pressure control in South Asian adults.

Cardiology Clinical Updates news

Amiloride vs Spironolactone for Resistant Hypertension: A New Alternative Backed by Randomized Trial Evidence

By MedXY 09/19/2025

A recent randomized clinical trial demonstrates amiloride's noninferiority to spironolactone in lowering systolic blood pressure in resistant hypertension, offering a promising alternative therapy.

Cardiology Clinical Updates news

Opt-Out vs Opt-In Behavioral Framing in Remote Blood Pressure Monitoring: Insights from a Pragmatic Randomized Clinical Trial

By MedXY 09/19/2025

A randomized clinical trial evaluating behavioral economic framing for remote blood pressure monitoring found no significant difference in patient enrollment or retention between opt-out and opt-in approaches, though both improved blood pressure control compared to usual care.

Cardiology Clinical Updates news Specialties

Repurposing Antihypertensive Drug Trazosin to Delay Vascular Aging: A Breakthrough in Atherosclerosis Management

By MedXY 09/18/2025

New research identifies transcription factor ATF3 as a key regulator of vascular smooth muscle cell aging and reveals low-dose trazosin, a commonly used antihypertensive, as a potential therapy to delay vascular aging and atherosclerosis progression via autophagy enhancement.

Cardiology Diabetes & Endocrinology Family Medicine & Nutrition Medical News news

Navigating the 2025 Best Diets: Tailored Eating Plans for Weight Loss, Hypertension, Menopause, and More

By MedXY 09/18/2025

The 2025 Best Diets ranking identifies optimal eating plans tailored to specific health needs, such as weight loss, high blood pressure, menopause, and digestive health, emphasizing scientifically backed, sustainable dietary patterns.

Cardiology Clinical Updates Diabetes & Endocrinology Specialties

Neutrophil Counts and Type 2 Diabetes Remission: Long-Term Benefits of Mediterranean Diet in Coronary Heart Disease Patients from the CORDIOPREV Study

By MedXY 09/18/2025

Lower neutrophil counts predict greater type 2 diabetes remission with a Mediterranean diet in coronary heart disease patients, highlighting immune involvement in metabolic improvement over 5 years.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Cardiology news Specialties

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Cardiology news Specialties

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

By MedXY 09/17/2025

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.

Cardiology Clinical Updates news Specialties

MAR001: A Promising ANGPTL4 Inhibitor for Safe and Effective Lipid Lowering

By MedXY 09/17/2025

Phase 1 and 1b/2a trials demonstrate that MAR001, an ANGPTL4 inhibitory antibody, safely reduces triglycerides and remnant cholesterol, supporting its potential to lower ASCVD risk beyond current therapies.

Cardiology Family Medicine & Nutrition Specialties

Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study

By MedXY 09/16/2025

A one-year DASH diet intervention led to sustained suppression of proatherogenic chemokine CXCL4 and fewer major cardiovascular events over six years despite reduced adherence and partial loss of initial benefits in nonobstructive CAD patients.

Cardiology Critical Care Medical News news Specialties

Sudden Death Is Not So Sudden: Understanding, Preventing, and Responding to Cardiac Arrest

By MedXY 09/14/2025

Sudden death, often caused by heart conditions, is typically the culmination of gradual damage. This article explores warning signs, emergency response, and crucial prevention strategies to protect your heart and save lives.

AI Cardiology Specialties

Harnessing Machine Learning to Predict High-Risk Coronary Artery Disease: Insights from the SCOT-HEART Trial

By MedXY 09/14/2025

Machine learning models trained on clinical data improve prediction of coronary artery disease on CT scans compared to traditional risk scores, potentially guiding better resource utilization in cardiovascular care.

AI Cardiology news Specialties

Harnessing AI: LLM-Based Conversational Agents Reduce Depression and Anxiety Among Young Adults in Short Video App Trial

By MedXY 09/14/2025

A 28-day RCT demonstrates that a conversational AI trained on a large language model effectively reduces mild depression and anxiety symptoms in young adults through dialog interventions integrated in short video apps.

Cardiology General Surgery news Specialties

Unexpected Risks of Postoperative 20% Albumin Infusion in High-Risk Cardiac Surgery Patients: Insights from the ALBICS AKI Trial

By MedXY 09/13/2025

The ALBICS AKI trial reveals that postoperative infusion of 20% albumin increases acute kidney injury risk in high-risk cardiac surgery patients, challenging prior assumptions about albumin's nephroprotective role in this setting.

Cardiology Specialties

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.

Cardiology Clinical Updates Family Medicine & Nutrition Radiology Specialties

CT Angiography Enhances Lifestyle and Prevention Uptake in Cardiovascular Risk Management: Insights from SCOT-HEART 2 Substudy

By MedXY 09/13/2025

A nested substudy from SCOT-HEART 2 reveals coronary CT angiography modestly improves healthy lifestyle adherence, preventive therapy acceptance, and risk factor modification compared to traditional cardiovascular risk scoring in asymptomatic individuals at risk.